Navigation Links
Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
Date:4/28/2009

oduct candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as BPH. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials will not support approval for a marketing license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a marketing license has been applied, the risk that the results of a clinical trial may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are a
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
2. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
3. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
4. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
5. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
8. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
9. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
10. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... , July 4, 2015 A ... of hypertension, diabetes and thyroid disorders in Central and ... educational platforms and a major conference dedicated to these ... Manage Diabetes Online , Manage Hypertension Online ... developed and operated by EXCEMED - combine ...
(Date:7/3/2015)... 3, 2015 Un fournisseur ... que sont l,hypertension, le diabète et les troubles ... éducatives gratuites et d,une conférence majeure dédiée à ... ) , Les formations ... Prendre en charge l,hypertension en ligne ...
(Date:7/3/2015)... MUMBAI , July 3, 2015 /PRNewswire/ ... gab heute bekannt, vorbehaltlich bestimmter Abschlussbedingungen eine ... Russland erworben zu haben. Mit dieser Übernahme ... der mit einem Umsatz von 765 Mrd. ... größten Pharmamärkten der Welt gehörte (IMS Health). ...
Breaking Medicine Technology:Combating Three Major Chronic Diseases in Central and South-East Asia With Medical Education 2Lutter contre trois maladies chroniques majeures en Amérique latine grâce à la formation médicale 2Lutter contre trois maladies chroniques majeures en Amérique latine grâce à la formation médicale 3Lupin übernimmt Biocom aus Russland 2Lupin übernimmt Biocom aus Russland 3
... 2a Clinical Trial at UCSD, NOVATO, ... or the "Company") (OTC Bulletin Board:,RPTP), today ... (the,"Agreement") with the University of California, San ... trial to evaluate a delayed-release preparation,of cysteamine ...
... Corporation, a,Georgia-based biotech company, announced today a ... collaboration with Cato Research Ltd.,its global contract ... will help support continued development of Abeome,s ... vastly improves the development of,monoclonal antibodies and ...
Cached Medicine Technology:Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 2Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 3Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 4Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 5Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic 2
(Date:7/6/2015)... ... , ... “ TapGlance ” was featured on NewsWatch as part of its ... market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology ... helps users visualize what rooms will look like before they even start renovating.. , ...
(Date:7/6/2015)... ... , ... June 22, 2015, Fox News in a report titled “ Female Hair Loss Needs to ... a quarter of all women in the U.S. will suffer from thinning hair or hair ... discussed. One woman, a former beauty queen, who was interviewed for the report began losing ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... ... care from nurses or midwives, yet there is a large gap between the ... midwifery research required to improve health outcomes and reduce unnecessary or ineffective treatments ...
(Date:7/6/2015)... ... ... Olive Fertility Centre is proud to announce that Olive medical director Dr. ... the department of Family Practice. , “This award is a real honour,” says Dr ... is changing so rapidly and we are also developing new models of patient-centred care ...
(Date:7/6/2015)... ... July 06, 2015 , ... Longevity, the highest ... with Woodbridge Walk-In Urgent Care to offer on-site health screenings. These ultrasound screenings ... Screenings are affordable and accurate and run about an hour long with same ...
Breaking Medicine News(10 mins):Health News:Create a Space with TapGlance, a Revolutionary Interior Design Application 2Health News:The Stigma of Female Hair Loss and Hair Restoration Solutions 2Health News:Columbia Nursing Nairobi Summit: Setting a Clinical Research Agenda for Africa 2Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:Woodbridge Walk-In Offers Affordable Early Detection Health Screenings Through Longevity 2
... ... of postmortem procedures , ... AZ (Vocus) February 4, 2010 -- Doctors or pathology technicians perform autopsies to diagnose any ... to the decedent’s death. The postmortem examination is of great importance to the family of ...
... ... risks associated with use of popular GlaxoSmithKline diabetes drug , ... Mineola, NY (Lexis Nexis) February 4, 2010 ... of opinions concerning the safety of its much touted diabetes drug Avandia , ...
... This ... expertise in the field of Lower Gastrointestinal, Urological and Sexual Dysfunction disorders. , ... (PRWEB) February 4, 2010 -- In an ... field of Lower Gastrointestinal, Urological and Sexual Dysfunction disorders with colleagues and patients around the ...
... (February 4, 2010) In a study to be presented today ... Meeting , in Chicago, researchers will unveil findings that detail an ... near-term scheduled births that did not have an appropriate medical ... by induction of labor, has been on the rise in recent ...
... COPD MAY BE OVERSTATED , Inhaled ... obstructive pulmonary disease (COPD). However, new research suggests that ICS ... patients with COPD. Researchers from India conducted a metaanalysis of ... versus placebo in prevention of COPD exacerbations. The use of ...
... CHICAGO, Ill. (February 4, 2010) In a study to ... annual meeting, The Pregnancy Meeting , in Chicago, researchers will ... treatment for depression during pregnancy. "Depression during pregnancy is ... both the mother and the baby as well as the ...
Cached Medicine News:Health News:Author Presents a Practical Guide for Postmortem Examinations 2Health News:New Scientific Studies Show Further Evidence of Avandia Dangers 2Health News:New Scientific Studies Show Further Evidence of Avandia Dangers 3Health News:International Pelvic Floor Muscle Expert Presents Live Webinars on Telemedecine 2Health News:International Pelvic Floor Muscle Expert Presents Live Webinars on Telemedecine 3Health News:Report documents statewide initiative to reduce near-term scheduled births 2Health News:News briefs from the February issue of Chest 2Health News:Acupuncture found effective against depression during pregnancy 2
Microseal 'F' foil, seals plates for cold storage (or cycling >25l), disposable, pkg of 100...
... Applied Biosystems has developed a comprehensive ... when using sequence detection systems (SDS) ... simple and easy to follow. Many ... concentration and the thermal cycling protocol ...
Microporous tape sheets for covering 96-well plates, square-well or flat-bottom blocks.;...
ThermalSeal RT (2mil) is Optically Clear for Real Time PCR and easy to apply. Works for all plates....
Medicine Products: